Innate and adaptive immune responses depend on the ability of Toll-like receptors (TLRs) to discriminate among different classes of microbial products and initiate specific signaling cascades. While microbial products with no equivalent in mammalian cells, such as the components of the bacterial wall, are recognized by surface TLRs (TLR1, TLR2, TLR4, TLR5 and TLR6), pathogen-derived nucleic acids are sensed by intracellular TLRs (TLR3, TLR7, TLR8 and TLR9). The recognition of nucleic acids by intracellular TLRs has the potential to trigger autoimmune disease through interaction with self nucleic acids 1 . To avoid inappropriate activation of endosomal TLRs, their trafficking is tightly controlled. Thus, in basal conditions, the receptors are located in the endoplasmic reticulum (ER) and translocate to endocytic vesicles only after stimulation of the cell by TLR ligands. Although all intracellular TLRs reside in the ER 2,3 , the trafficking pathways that move the receptors into the endocytic pathway show considerable variation among intracellular TLRs 4-6 . For example, TLR7 traffics from Golgi stacks directly to endosomes through use of the clathrin adaptor AP4, whereas the TLR9 is directed to the cell surface and reaches the endosomes via clathrin-dependent endocytosis mediated by the adaptor complex AP2 (ref. 6). In addition to transfer into the endocytic pathway, a second step that controls the activation of endosomal TLRs is their partial proteolysis by an array of proteases specific for each TLR 5,7-12 .
Innate and adaptive immune responses depend on the ability of Toll-like receptors (TLRs) to discriminate among different classes of microbial products and initiate specific signaling cascades. While microbial products with no equivalent in mammalian cells, such as the components of the bacterial wall, are recognized by surface TLRs (TLR1, TLR2, TLR4, TLR5 and TLR6), pathogen-derived nucleic acids are sensed by intracellular TLRs (TLR3, TLR7, TLR8 and TLR9). The recognition of nucleic acids by intracellular TLRs has the potential to trigger autoimmune disease through interaction with self nucleic acids 1 . To avoid inappropriate activation of endosomal TLRs, their trafficking is tightly controlled. Thus, in basal conditions, the receptors are located in the endoplasmic reticulum (ER) and translocate to endocytic vesicles only after stimulation of the cell by TLR ligands. Although all intracellular TLRs reside in the ER 2, 3 , the trafficking pathways that move the receptors into the endocytic pathway show considerable variation among intracellular TLRs [4] [5] [6] . For example, TLR7 traffics from Golgi stacks directly to endosomes through use of the clathrin adaptor AP4, whereas the TLR9 is directed to the cell surface and reaches the endosomes via clathrin-dependent endocytosis mediated by the adaptor complex AP2 (ref. 6 ). In addition to transfer into the endocytic pathway, a second step that controls the activation of endosomal TLRs is their partial proteolysis by an array of proteases specific for each TLR 5, [7] [8] [9] [10] [11] [12] .
Although it is mentioned less often, the intracellular trafficking of its ligand also controls the activation of TLR9. TLR9 ligands (CpG dinucleotides) are internalized via clathrin-mediated endocytosis in early endosomes and translocate to late LAMP + compartments 2 . The activation of TLR9 depends on the localization of CpG, since abolishing the translocation of CpG to LAMP + compartments by specific inhibitors decreases TLR9 signaling 13, 14 . Thus, the intracellular trafficking of both the ligand and the receptor is essential for the control of TLR9 activation.
The complexity of the trafficking of TLR9 and CpG is rendered possible by the diversity and plasticity of the endocytic system. This system includes early endosomes that fuse to generate the sorting endosomes. From there, cargos are directed to different organelles, such as Rab4 + quickly recycling endosomes, Rab11 + slowly recycling endosomes, the trans-Golgi network or lysosomes. In addition to those universal routes of endosome trafficking, specialized cells such as dendritic cells (DCs) display specific, albeit poorly characterized endosomal populations that affect TLR function, such as VAMP3 + vesicles, which are involved in TLR9 trafficking 15 .
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An abundant endocytic population present in DCs that has not yet been investigated in the context of TLR signaling is the slowly recycling endosomes. These are characterized by the presence of insulinresponsive aminopeptidase (IRAP ), a type II transmembrane protein composed of a catalytic site located in the endosomal lumen and a cytosolic domain of 110 amino acids. In DCs, IRAP + endosomes are rapidly recruited to DC phagosomes, where the enzymatic activity of IRAP is involved in antigen processing during cross-presentation by major histocompatibility complex class I (refs. 16, 17) .
The regulated trafficking of IRAP depends on the cytosolic domain of the enzyme, which has been shown to interact with several proteins involved in vesicle formation or in cytoskeleton remodeling, such as the golgin p115 (ref. 18) , vimentin 19 and FHOD1 ('formin-homologydomain-containing protein 1') 20 . Whether these proteins and their interaction with the cytosolic domain of IRAP are involved in the trafficking of IRAP + endosomes is not known.
We sought to determine if IRAP has s a role in endosomal trafficking and activation of TLRs. We found that the early steps in TLR9 trafficking and CpG endocytosis required IRAP. The absence of IRAP affected the trafficking of both CpG and TLR9, which led to a substantial increase in TLR9 signaling in vitro and in vivo following stimulation of TLR9. Thus, by anchoring TLR9 + IRAP + endosomes to the actin cytoskeleton, IRAP limited the activation of TLR9. These findings provide a mechanistic explanation for the link between mutations in the gene encoding IRAP and autoimmune disorders associated with TLR9 (ref. 21 ) and identify factors and cellular pathways not previously known to be involved in the activation of TLR9.
RESULTS
Enhanced TLR9 response after deletion of IRAP
To address the role of IRAP in TLR signaling, we stimulated wild-type and IRAP-deficient bone-marrow-derived dendritic cells (BMDCs) with specific TLR ligands: the synthetic RNA duplex poly(I:C), for TLR3; imiquimod, for TLR7; CpG-B, for TLR9; and lipopolysaccharide (LPS), for TLR4. We then measured production of the pro-inflammatory cytokines IL-6, IL-12p40 and TNF by those cells. Although deletion of IRAP did not affect the TLR3-or TLR4-dependent production of pro-inflammatory cytokines, it enhanced the production of proinflammatory cytokines driven by TLR9 (Fig. 1a) and activation of TLR7 (Supplementary Fig. 1a) . These results suggested that IRAP affected the transcription-factor NF-κB pathway downstream of TLR9 and probably also TLR7.
Since the production of type I interferons depends on signaling by TLR9 through the transcription factor IRF7, we sought to determine whether deletion of IRAP affected interferon (IFN-β). We measured the production of IFN-β by wild-type and IRAP-deficient BMDCs stimulated with ligands for TLR3, TLR4 or TLR9. Deletion of IRAP significantly increased only the production of IFN-β driven by TLR9, not that driven by TLR3 or TLR4 (Fig. 1b) . Thus, IRAP disturbed the amplitude of the production of both pro-inflammatory cytokines and type I interferons in a TLR9-dependent manner in BMDCs.
To address whether the hypersensitivity of IRAP-deficient cells to TLR9 ligands was restricted to BMDCs, we purified conventional DCs (cDCs) and plasmacytoid DCs (pDCs) from the spleen and stimulated them with a TLR9 agonist. When incubated with CpG, IRAP-deficient spleen cDCs (Fig. 1c) and pDCs ( Fig. 1d) produced significantly larger amounts of pro-inflammatory cytokines and INF-α than did their wild-type counterparts. These results demonstrated that IRAP controlled the activation of TLR9 in all DC subsets tested.
At least two mechanisms could account for the enhanced TLR9 response of IRAP-deficient DCs. IRAP + endosomes might store pro-inflammatory cytokines and control their secretion, or they might directly influence the trafficking of TLR9 or CpG. We analyzed the intracellular localization of pro-inflammatory cytokines in wild-type and IRAP-deficient cells. Neither IL-12 nor IL-6 localized together with IRAP, but they were present in Golgi stacks, as previously reported 22 ( Supplementary Fig. 1b,c) . Thus, IRAP + endosomes were probably not involved in the trafficking or secretion of IL-6 or IL-12p40 and might be involved in a step upstream of their synthesis. In support of that hypothesis, we found that DCs lacking IRAP had significantly higher expression of mRNA encoding pro-inflammatory cytokines than did wild-type DCs after stimulation with CpG, but not after stimulation with LPS (Fig. 1e,f) .
The higher expression in cytokine-encoding mRNA in IRAP-deficient cells following stimulation of TLR9 should be correlated with enhanced TLR9 signaling. To specifically investigate TLR9 signaling, we assessed the association of the adaptor MyD88 with the transcription factors NF-κB and IRF7. A proximity-ligation assay, which detects protein complexes in situ 23 , demonstrated significantly greater association of MyD88 with NF-κB ( Fig. 2a) and of MyD88 with IRF7 ( Fig. 2b) in IRAP-deficient cells than in wild-type cells.
As a consequence of TLR activation, the mitogen-activated protein kinase ERK is rapidly phosphorylated. Indeed, phosphorylation of ERK was greater in IRAP deficient cells than in wild-type cells after stimulation with CpG, as detected by immunoblot analysis (Fig. 2c) . In addition, the final step in the activation of NF-κB, phosphorylation of the inhibitory cytoplasmic NF-κB chaperone IκBα, was also significantly greater in IRAP-deficient cells than in wildtype cells after treatment with CpG, but not after treatment with LPS (Fig. 2d) . Together these results indicated enhanced TLR9 signaling in the absence of IRAP.
TLR9 inflammatory phenotype of IRAP-deficient mice
Our in vitro data demonstrated regulation of TLR9 signaling by IRAP. We next addressed whether IRAP-deficient (Lnpep −/− ) mice display enhanced activation of TLR9. To investigate this, we measured IL-6 in the serum of wild-type and IRAP-deficient mice 2 h after intravenous injection of PBS, CpG-B or LPS. Although wild-type and IRAPdeficient mice responded identically to the injection of PBS or LPS, stimulation of TLR9 led to higher concentrations of IL-6 in the serum of mice lacking IRAP than in their wild-type counterparts (Fig. 3a) .
We sought to determine if the exacerbated proinflammatory TLR9 signaling might affect the innate immune response during a bacterial infection. Pseudomonas aeruginosa is a Gram-negative bacterium that activates several TLRs, including TLR9, on alveolar macrophages (AMs) and epithelial cells 24 . TLR9-deficient mice have been shown to be resistant to infection with P. aeruginosa, which suggests that TLR9 signaling can have deleterious effects in this model 25 . To determine whether deletion of IRAP would affect survival after bacterial pulmonary infection, we intranasally inoculated IRAP-deficient and wildtype mice with 1 × 10 6 colony-forming units (CFU) of P. aeruginosa and monitored their survival. At least 36% of the wild-type mice survived during the 2 weeks of observation, while all IRAP-deficient mice died within 72 h of infection (Fig. 3b) . We then investigated the correlation between mouse survival and the inflammatory response monitored in the lungs at 24 h after infection. The broncho-alveolar lavage (BAL) fluid of infected IRAP-deficient mice contained higher concentrations of the inflammatory cytokines CXCL1, IL-6, TNF and IL-1β than that of wild-type mice (Fig. 3c) . Since AMs are the first innate immune cells to encounter bacteria in the lungs, we isolated AMs and assessed their cytokine production upon stimulation of TLR9 or TLR4 in vitro. While a response was barely detectable in AMs isolated from wild-type mice, IRAP-deficient AMs secreted substantially higher concentrations of all pro-inflammatory cytokines than did wild-type AMs, after stimulation with CpG (Fig. 3d) . In contrast, IRAP deficiency did not alter the secretion of IL-6 or TNF after stimulation with LPS (Fig. 3d) , which indicated that the hyperinflammatory phenotype produced was restricted to TLR9.
To control for a potential difference between the two mouse strains in their ability to clear bacteria from the lungs, we measured the A r t i c l e s pulmonary bacterial load and found it was identical in IRAP-deficient mice and wild-type mice (Fig. 3e) . Consistent with the identical ability of both strains to clear bacteria, infection with P. aeruginosa led to similar accumulation of neutrophils and macrophages-monocytes in the airways of both groups (Supplementary Fig. 2a ). In addition, myeloperoxidase activity, which mirrors neutrophil degranulation, in BAL fluid from wild-type mice was similar that in BAL fluid from IRAP-deficient mice (Supplementary Fig. 2b ). Together these results suggested that following infection with P. aeruginosa, IRAP-deficient mice died earlier, probably because of an excessive inflammatory response driven by hyper-stimulation of TLR9.
No involvement of IRAP's enzymatic activity in TLR9 activation
Our results showed that proper regulation of TLR9 signaling required IRAP. Since IRAP is an aminopeptidase, we sought to determine if the enzymatic activity of IRAP was involved in controlling the activation of TLR9. To investigate this possibility, we assessed the effect of an inactive form of IRAP on the activation of TLR9. IRAP contains the canonical zinc-binding amino acid motif His-Glu-Leu-Ala-His (HELAH), which is essential for its enzymatic activity 26 . Like wildtype IRAP, a mutant form of IRAP in which that HELAH sequence was changed to HALAH (with substitution of alanine for the glutamic acid at position 465) localized together with Stx6 ('syntaxin 6'), a SNARE receptor ('soluble N-ethylmaleimide-sensitive factor-attachment protein receptor') of IRAP + endosomes 16, 17 (Fig. 4a) . Both wild-type IRAP and the mutant form of IRAP were expressed well, as shown by immunoblot analysis with antibody to IRAP (anti-IRAP) (Fig. 4b) but the mutant form was enzymatically inactive (Fig. 4c) . When we reconstituted IRAP-deficient BMDCs with wild-type IRAP (Fig. 4d) or enzymatically inactive IRAP (Fig. 4e) , the production of pro-inflammatory cytokines upon stimulation with CpG was similar to that in wild-type cells. These results demonstrated that the enzymatic activity of IRAP was not involved in controlling the activation of TLR9.
CpG and TLR9 are cargos of IRAP + endosomes Since IRAP's enzymatic activity was not involved in the activation of TLR9, we sought to determine if IRAP could interfere directly with the trafficking of TLR9 or CpG. Analysis of fluorescein-isothiocyanate (FITC)-tagged CpG (CpG-FITC) by confocal microscopy demonstrated that CpG substantially localized together with IRAP. After 20 min of endocytosis, half of the internalized CpG was present in IRAP + endosomes, where it was retained for at least 1 h (Fig. 5a) . Concomitant with that IRAP-CpG colocalization, 20% of green-fluorescent-protein (GFP)-tagged TLR9 (TLR9-GFP) was present in IRAP + endosomes 20 min after stimulation of the cells with CpG (Fig. 5b) . While CpG was a major and persistent cargo of IRAP + endosomes, TLR9 was not retained in IRAP + endosomes for 1 h (data not shown).
Since both TLR9 and its ligand trafficked via IRAP + endosomes, we sought to determine if IRAP + endosomes contained VAMP3, a marker of an endosomal population through which TLR9 traffics toward lysosomes 15 . IRAP, as well as the small GTPase Rab14 and Stx6, two others markers of IRAP + endosomes in DCs 16, 17 , partially colocalized with VAMP3 + endosomes (Supplementary Fig. 3 ). These results suggested that IRAP + endosomes are a previously unknown intermediate compartment between early endosomes and the final destination of TLR9, which is the LAMP + lysosome. That conclusion is also supported by the absence of colocalization of IRAP and LAMP shown previously 16, 17 .
Increased lysosomal processing of TLR9 in the absence of IRAP Since CpG and TLR9 are cargos of IRAP + endosomes, we sought to determine if deletion of IRAP would change the trafficking of CpG and TLR9. Analysis of CpG-FITC trafficking demonstrated that the proportion of TLR9 ligand transported to LAMP + vesicles was significantly greater in IRAP-deficient cells than in wild-type cells, an effect that was obvious at early time points (Fig. 6a) . The accelerated transport to lysosomes of CpG in IRAP-deficient DCs correlated with a change in the intracellular distribution of TLR9-GFP, which was present in lysosomes even in the absence of CpG stimulation (Fig. 6b) .
The presence of TLR9 in the LAMP + compartment correlates with proteolytic generation of the active C-terminal fragment of this receptor in DCs and macrophages 7, 8, 11, 12, 27 . In agreement with the lysosomal localization of TLR9 in unstimulated IRAP-deficient cells, we found that in IRAP-deficient primary mouse embryonic fibroblasts transfected to express TLR9-GFP and the ER transmembrane protein UNC93B tagged with the red fluorescent protein mCherry, the majority of immunoprecipitated TLR9-GFP corresponded to the processed form of TLR9, but this result was not obtained for their wild-type counterparts (Fig. 6c) . As expected, given the functional assays of TLR stimulation (Fig. 1a,b) , TLR3 did not localize together with IRAP, and the intracellular localization of TLR3 was not affected by the absence of IRAP (Supplementary Fig. 4) . Thus, in the absence of IRAP, TLR9 was targeted to lysosomes without cell stimulation, but TLR3 was not.
To ensure that the lysosomal localization of TLR9 in IRAP-deficient cells was not the consequence of the expression of TLR9-GFP via nucleofection, we investigated the localization of endogenous TLR9. Since the only antibody specific for TLR9 (Fig. 6d) was not sensitive enough to detect TLR9 in whole-cell lysates, we isolated early and late phagosomes from wild-type and IRAP-deficient DCs. Although in the absence of CpG, TLR9 was not recruited to phagosomes in wild-type cells, we detected the active C-terminal form of TLR9 in IRAP-deficient late phagosomes (Fig. 6e) . Thus, similar to movement of the TLR9-GFP fusion protein, endogenous TLR9 was recruited to phagolysosomes without treatment of cells with CpG in the absence of IRAP. Notably, when the cells were stimulated with CpG, the recruitment of TLR9 to early and late phagosomes in wild-type cells was identical to that in IRAP-deficient cells (Fig. 6e) . However, despite the similar recruitment of endogenous TLR9 to phagolysosomes in wild-type and IRAP-deficient cells upon treatment with CpG, TLR9 signaling was higher in IRAP-deficient cells than in wild-type cells (Fig. 2) . This apparent contradiction could be explained by enhanced accessibility of TLR9 to CpG in IRAP-deficient cells, as suggested by the accelerated translocation of internalized CpG-FITC to lysosomes (Fig. 6a) . Together these results demonstrated that the lack of IRAP enhanced the processing of TLR9.
Less retention of CpG and TLR9 in IRAP-deficient endosomes
Since the consequences of IRAP on the hyperactivation of TLR9 could have arisen from the effects of IRAP on the trafficking of early endosomes, we sought to determine if the early steps of the trafficking of CpG and TLR9 were modified by depletion of IRAP. To analyze this, we used the early endosomal antigen EEA1, a tethering factor known to be involved in homotypic and heterotypic fusion events of early endosomes. The recruitment of EEA1 to endosome is a mandatory step in endosomal maturation and fusion to lysosomes, since inhibition of EEA1 activity blocks phagosome maturation 28 . Nevertheless, a fraction of EEA1 + endosomes display a low maturation rate and do 
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A r t i c l e s not fuse rapidly to late endosomes 29 . To visualize the trafficking of TLR9 and CpG in EEA1 + endosomes, we obtained BMDCs from mice with transgenic expression of TLR9-GFP and pulsed the cells with CpG-biotin. The uptake of CpG into wild-type BMDCs was similar to that in IRAP-deficient BMDCs (Fig. 7a) , which prompted us to deplete cells of IRAP via lentivirus encoding shRNA targeting IRAP in BMDCs expressing TLR9-GFP (Fig. 7b) . Colocalization analysis of TLR9-GFP and EEA1 showed that in cells depleted of IRAP, TLR9 displayed a vesicular staining in subdomains of EEA1 + endosomes in the absence of CpG, but this was not true for cells treated with control (non-targeting) shRNA (Fig. 7c) . Following incubation with CpG, the trafficking of CpG was also affected by depletion of IRAP: although in cells treated with control shRNA, 25% of internalized CpG remained for 2 h in EEA1 + endosomes, in cells depleted of IRAP, CpG was rapidly transferred from EEA1 + endosomes to TLR9 + vesicles (Fig. 7c) . As a consequence of the rapid transfer of CpG to TLR9 + vesicles in cells depleted of IRAP, the colocalization of CpG and TLR9 was three times higher in cells depleted of IRAP than in cells treated with control shRNA (Fig. 7d) . Thus, depletion of IRAP facilitated not only the processing of TLR9 but also the access of TLR9 to its ligand.
Interaction of IRAP with FHOD4
Collectively, the results reported above highlighted a role for IRAP in the retention of TLR9 and CpG in EEA1 + endosomes that was independent of its enzymatic activity. We reasoned that the effect of IRAP on the activation of TLR9 might be mediated by interactions with cytosolic proteins. Two cytoskeleton factors have been identified as interacting with the cytosolic domain of IRAP: vimentin 19 and FHOD1 (ref. 20) . Vimentin forms intermediate filaments, cytoskeleton components that are important for anchoring intracellular organelles 30 . Formins of the FHOD family are actin-polymerization factors and are involved in anchoring vesicles to the actin cytoskeleton 31 . Thus, vimentin and formins might have a role in the control of IRAP-mediated trafficking of TLR9. Proximity-ligation assays and co-immunoprecipitation experiments with fibroblasts and in DCs failed to show a robust interaction between IRAP and vimentin (data not shown), which indicated that the IRAP-vimentin interaction that has been demonstrated in adipocytes 19 might be specific to that cell type. 
A r t i c l e s
To investigate the FHOD1-IRAP interaction in DCs, we first explored the expression of FHOD1 in various cell types as reported in the gene-expression database of the Immunological Genome Project (ImmGen) consortium 32 (Fig. 8a) . The mRNA-expression data recovered from ImmGen showed that while expression of mRNA encoding FHOD1 is restricted to a subset of macrophages, mRNA encoding FHOD4, a formin from the same family, has a wider distribution and higher expression in monocytes and DCs (https://www.immgen. org/Databrowserpage.swf). Consequently, we assessed the interaction between IRAP and FHOD4. Endogenous FHOD4, as well as a FHOD4-GFP fusion protein, interacted with IRAP, as demonstrated by reciprocal co-immunoprecipitation ( Fig. 8b and Supplementary  Fig. 5a ) and by proximity-ligation assay in situ 23 (Fig. 8c and  Supplementary Fig. 5b ). Confocal microscopy showed that FHOD4 was recruited to IRAP + endosomes, together with a vesicular actin coat labeled by phalloidin (40% (± 5%) (mean ± s.e.m.) of IRAP colocalized with FHOD4; Fig. 8d) . These results suggested that FHOD4 might anchor IRAP + endosomes to the actin cytoskeleton.
To investigate if the FHOD4-IRAP interaction was involved in the activation of TLR9 in DCs, we knocked down FHOD4 in BMDCs from mice with transgenic expression of TLR9-GFP. The abundance of FHOD4 was reproducibly reduced by 95% (± 10%) (mean ± s.e.m.) in the cells transduced with shRNA targeting FHOD4 (Fig. 8e) . In the absence of FHOD4 and stimulation with CpG, 40% (±5%) (mean ± s.e.m.) of the endogenous TLR9-GFP was in the cleaved form (Fig. 8f) . In agreement with the increased basal processing of TLR9, the GFP-fused TLR9 was present in lysosomes in cells depleted of FHOD4 (Fig. 8g) . Thus, the trafficking and processing of TLR9 were affected by depletion of FHOD4, as found for the depletion of IRAP.
Given the effect of the depletion of FHOD4 on the localization of TLR9, we expected to find an enhanced TLR9-driven inflammatory response in BMDCs depleted of FHOD4. After incubation with CpG, cells depleted of FHOD4 (via shRNA) secreted significantly more proinflammatory cytokines than did cells transduced with control (nontargeting) shRNA ( Fig. 8h and Supplementary Fig. 6a) . Consistent with the low expression of FHOD1 in BMDCs (Supplementary Fig. 6b ), its depletion did not affect the localization or activation of TLR9-GFP (Supplementary Fig. 6c,d) . These results suggested that IRAP anchored endosomal vesicles to the actin cytoskeleton through its specific interaction with FHOD4 and slowed their transport to lysosomes (Supplementary Fig. 7) . A major effect of these molecular interactions was to ensure limited interaction between TLR9 and its ligand, which prevented hyper-inflammation.
DISCUSSION
The recognition of host nucleic acids by intracellular TLRs is a risk for autoimmunity. For example, inappropriate activation of endosomal TLRs by self DNA has a major role in the inflammation that occurs in systemic lupus erythematous, arthritis and psoriasis 33 . To avoid hyperactivation of TLRs, their encounter with the ligands and ability to signal must be tightly regulated. TLR9, like other intracellular TLRs, exits the ER by interacting with UNC93B 34 . Unlike the movement of other TLRs, the TLR9-UNC93B complex reaches the cell surface and is later internalized into a poorly characterized endosomal compartment through AP2-mediated endocytosis 6 .
In this study, we identified IRAP as a regulator of the intracellular trafficking of CpG and TLR9 and the in vivo activation of TLR9. IRAP deficiency led to the rapid transport of internalized CpG to lysosomes and to the localization of TLR9 in lysosomes, where TLR9 was cleaved into its active C-terminal form in the absence of its ligand CpG. We observed this aberrant trafficking and processing of TLR9 not only for TLR9-GFP but also for endogenous TLR9 detected with anti-TLR9. normally is retained in IRAP + endosomes for a long time. The aberrant trafficking of both the ligand and the receptor led to an uncontrolled inflammatory response to TLR9 ligands, which culminated in animal death following infection with P. aeruginosa, a bacterium sensed by TLR9 (ref. 25) . Together our results showed that IRAP was needed to avoid excessive TLR9-driven inflammatory responses. In view of these results, it is conceivable that IRAP has a role in human autoimmune pathologies through its effects on TLR9 signaling. The identification of a genetic association between psoriasis, one of the autoimmune disorders linked to activation of TLR9, and a nonsense mutation in LNPEP (which encodes IRAP) is consistent with this hypothesis 21 .
Our colocalization experiments defined an endosomal compartment that was described by the presence of IRAP, Rab14 and Stx6 and partially overlapped with VAMP3 + and EEA1 + endosomes. VAMP3 and TLR9 have been shown to colocalize in an intermediate step of the route that TLR9 follows toward lysosomes and that depends on the adaptor AP3 (ref. 15) . Our data suggested that IRAP delayed the trafficking of CpG and TLR9 from EEA1 + endosomes to lysosomes, with important functional consequences. To understand how IRAP could mechanistically affect the dynamics of the early endosomal compartment in which CpG and TLR9 are retained, we screened for cytoskeletal proteins that might interact with IRAP and could interfere with endosomal motility. Indeed, given that the cytosolic tail of IRAP has been shown to interact with two cytoskeleton components, the actin-nucleation factor and formin FHOD1 (ref. 20) and the intermediate filament vimentin 19 , we hypothesized that these interactions ensure the anchoring of IRAP and TLR9 endosomes to cytoskeleton. Whereas the interaction of IRAP with vimentin was not detectable in DCs (data not shown), we found that IRAP bound to FHOD4.
Formins are major actin-nucleation factors that drive the assembly of actin monomers into filamentous structures and remain associated with the barbed end during filament elongation 35 . Knockdown of FHOD4 had effects similar to those of IRAP deletion on the trafficking of TLR9 and the cellular response to CpG. These results suggested that by promoting actin assembly on endosomes, FHOD4 prevented the transfer of endosomes to microtubules, delaying their retrograde transport toward lysosomes, as reported for the formin mDia1 (ref. 36) . Actin polymerization around endosomal vesicles containing TLR9 ligands has been shown to be also driven by the other key actin-nucleation factor, Arp2/3, and has been shown to be essential in limiting TLR9 signaling 37 . Both FHOD4 and Arp2/3 are activated by the same small GTPase of Rho family, Cdc42 (ref. 35) , which suggests that these two actin-remodeling factors might act together in the regulation of TLR9 signaling, as they do in phagocytic-cup formation 38 .
The intervention of FHOD4 via its interaction with IRAP in modulating TLR9 function has implications for potential links between extracellular stimuli, such as cytokines and the ability of TLR9 to respond to its ligands. It has been reported that TLR responses can be inhibited by extracellular stimuli, such as cytokines 39 or integrin ligation 40, 41 . Since the activation of Cdc42 occurs downstream of signaling via integrins, receptor tyrosine kinases or G-protein-coupled receptors 42 , it could affect actin polymerization and the anchoring of CpG + TLR9 + endosomes by IRAP. Thus, the anchoring of CpG + TLR9 + endosomes to the actin cytoskeleton might be essential in regulating TLR9-dependent cellular responses to the environment.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
